These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


217 related items for PubMed ID: 15228169

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical implications of thiopurine methyltransferase--optimization of drug dosage and potential drug interactions.
    Lennard L.
    Ther Drug Monit; 1998 Oct; 20(5):527-31. PubMed ID: 9780130
    [Abstract] [Full Text] [Related]

  • 3. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides.
    Duley JA, Florin TH.
    Ther Drug Monit; 2005 Oct; 27(5):647-54. PubMed ID: 16175140
    [Abstract] [Full Text] [Related]

  • 4. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
    Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Klein TE, Clinical Pharmacogenetics Implementation Consortium.
    Clin Pharmacol Ther; 2011 Mar; 89(3):387-91. PubMed ID: 21270794
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations.
    Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM.
    Clin Pharmacol Ther; 1987 Jan; 41(1):18-25. PubMed ID: 3467886
    [Abstract] [Full Text] [Related]

  • 7. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
    Dervieux T, Médard Y, Verpillat P, Guigonis V, Duval M, Lescoeur B, Suciu S, Vilmer E, Jacqz-Aigrain E.
    Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].
    Gisbert JP, González-Lama Y, Maté J.
    Gastroenterol Hepatol; 2006 Nov; 29(9):568-83. PubMed ID: 17129552
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
    Hanai H, Iida T, Takeuchi K, Arai O, Watanabe F, Abe J, Maruyama Y, Oohata A, Ikeya K, Kageoka M, Miwa I, Yoshirou S, Hosoda Y, Kubota T.
    Inflamm Bowel Dis; 2010 Aug; 16(8):1376-81. PubMed ID: 20049951
    [Abstract] [Full Text] [Related]

  • 13. Implementation of TPMT testing.
    Lennard L.
    Br J Clin Pharmacol; 2014 Apr; 77(4):704-14. PubMed ID: 23962279
    [Abstract] [Full Text] [Related]

  • 14. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update.
    Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, Moyer AM, Evans WE, Klein TE, Antillon-Klussmann FG, Caudle KE, Kato M, Yeoh AEJ, Schmiegelow K, Yang JJ.
    Clin Pharmacol Ther; 2019 May; 105(5):1095-1105. PubMed ID: 30447069
    [Abstract] [Full Text] [Related]

  • 15. Interindividual variability in TPMT enzyme activity: 10 years of experience with thiopurine pharmacogenetics and therapeutic drug monitoring.
    Chouchana L, Narjoz C, Roche D, Golmard JL, Pineau B, Chatellier G, Beaune P, Loriot MA.
    Pharmacogenomics; 2014 Apr; 15(6):745-57. PubMed ID: 24897283
    [Abstract] [Full Text] [Related]

  • 16. [New techniques for optimization of thiopurine therapy in leukemia and transplantation].
    Loennechen T, Lysaa RA, Giverhaug T, Sylte I, Mathiesen LE, Aarbakke J.
    Tidsskr Nor Laegeforen; 2002 Apr 30; 122(11):1107-10. PubMed ID: 12043054
    [Abstract] [Full Text] [Related]

  • 17. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
    Relling MV, Hancock ML, Rivera GK, Sandlund JT, Ribeiro RC, Krynetski EY, Pui CH, Evans WE.
    J Natl Cancer Inst; 1999 Dec 01; 91(23):2001-8. PubMed ID: 10580024
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic drug monitoring of 6-thioguanine nucleotides in paediatric acute lymphoblastic leukaemia: interest and limits].
    Fakhoury M, de Beaumais T, Médard Y, Jacqz-Aigrain E, Suivi Thérapeutique Pharmacologique de la Société Française de Pharmacologie et de Thérapeutique.
    Therapie; 2010 Dec 01; 65(3):187-93. PubMed ID: 20699069
    [Abstract] [Full Text] [Related]

  • 19. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
    Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.
    J Crohns Colitis; 2014 Feb 01; 8(2):120-8. PubMed ID: 23932783
    [Abstract] [Full Text] [Related]

  • 20. High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
    van Egmond R, Chin P, Zhang M, Sies CW, Barclay ML.
    Aliment Pharmacol Ther; 2012 May 01; 35(10):1181-9. PubMed ID: 22486532
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 11.